Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Cisplatin, and Cetuximab Induction in NSCLC
NCT00406302Phase 2Completed
- Sponsor
- Wolfgang Hilbe
- Start
- Jan 2007
- Primary completion
- Jun 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Wolfgang Hilbe. Started Jan 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00406302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406302.